Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359

HIV Clinical Trials

Volumn 8, Issue 2, 2007, Pages 63-67

  Haubrich, Richard H ^a,h   Jiang, Hongyu ^b   Swanstrom, Ronald ^c   Bates, Michael ^d   Katzenstein, David ^e   Petch, Leslie ^c   Fletcher, Courtney V ^f   Fiscus, Susan A ^c   Gulick, Roy M ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d MONOGRAM BIOSCIENCES   (United States)

^e STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hypersusceptibility; Phenotype; Virologic response

Indexed keywords

DELAVIRDINE; INDINAVIR; LAMIVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; HUMAN; IC 50; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; VIRUS LOAD;

ANTI-HIV AGENTS; DELAVIRDINE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MICROBIAL SENSITIVITY TESTS; REGRESSION ANALYSIS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 34250706943     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0802-63     Document Type: Article

References (12)

1. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 2003;37:113-128.
2. Cohen CJ, Hunt S, Sension M, et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS. 2002;16:579-588.
3. Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS. 2000;14:F83-93.
4. Meynard JL, Vray M, Morand-Joubert L, et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS. 2002;16:727-736.
5. Swanstrom R, Bosch RJ, Katzenstein D, et al. Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects. J Infect Dis. 2004;190:886-893.
6. Haubrich RH, Kemper CA, Hellmann NS, et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS. 2005;19:295-302.
7. Whitcomb JM, Huang W, Limoli K, et al. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. AIDS. 2002;16:F41-47.
8. Katzenstein DA, Bosch RJ, Hellmann N, Wang N, Bacheler L, Albrecht MA. Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs. AIDS. 2003;17:821-830.
9. Haubrich RH, Kemper CA, Hellmann NS, et al. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. AIDS. 2002;16:F33-40.
10. Gulick RM, Hu XJ, Fiscus SA, et al. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. J Infect Dis. 2000;182:1375-1384.
11. Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2000;44:920-928.
12. Bosch RJ, Downey GF, Katzenstein DA, Hellmann N, Bacheler L, Albrecht MA. Evaluation of outpoints for phenotypic hypersusceptibility to efavirenz. AIDS. 2003;17:2395-2396.